Beclomethasone (QVAR)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Asthma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (9)
Asthma
NCT03834012 · Adamis Pharmaceuticals Corporation
2019-02 – 2020-04 · Asthma
What this study did
NCT00394329 · Milton S. Hershey Medical Center
2006-11 – 2011-12 · Asthma
What this study did
NCT00109668 · Teva Branded Pharmaceutical Products R&D, Inc.
2004-07-31 – 2006-09-30 · Asthma
What this study did
NCT00094016 · Teva Branded Pharmaceutical Products R&D, Inc.
2004-10-31 – 2006-06-30 · Asthma
What this study did
Phase 2/3 (1)
Asthma
NCT00119496 · University of Glasgow
2005-07 – 2007-06 · Asthma
What this study did
Phase 2 (1)
Other / comorbidity
NCT01373008 · Bnai Zion Medical Center
2011-06 – 2016-06 · Bronchopulmonary Dysplasia
What this study did
Phase 4 (3)
Asthma
NCT01894048 · University of Dundee
2013-10-28 – 2018-06-25 · Asthma
What this study did
NCT01741285 · University Medical Center Groningen
2013-04 – 2015-12 · Asthma
What this study did
NCT00250341 · Teva Branded Pharmaceutical Products R&D, Inc.
2005-09-30 – 2007-09-30 · Asthma
What this study did
Early phase / not applicable (1)
Asthma
NCT01224951 · Universitaire Ziekenhuizen KU Leuven
2011-01 – 2018-07 · Asthma
What this study did
Used as active comparator (7)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Phase 2 (3)
Asthma
NCT03084718 · Chiesi Farmaceutici S.p.A.
2017-07-28 – 2018-12-05 · Asthma
What this study did
NCT02787967 · Chiesi Farmaceutici S.p.A.
2016-08 – 2017-06 · Asthma
What this study did
NCT01468272 · Chiesi Farmaceutici S.p.A.
2011-11 – 2012-08 · Asthma in Children
What this study did
Phase 1 (1)
Appears in other studies (20)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (14)
Asthma
NCT04886999 · Chiesi Farmaceutici S.p.A.
2022-02-24 – 2023-02-01 · Asthma
What this study did
NCT03835871 · Adamis Pharmaceuticals Corporation
2019-02 – 2020-05 · Asthma
What this study did
NCT02139644 · Teva Branded Pharmaceutical Products R&D, Inc.
2014-06 – 2015-09 · Asthma
What this study did
NCT01113489 · Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy
2010-04 – 2010-07 · Asthma, Allergic Rhinitis
What this study did
NCT00862264 · Chiesi Farmaceutici S.p.A.
2004-08 – 2005-09 · Asthma
What this study did
NCT00394368 · Chiesi Farmaceutici S.p.A.
2004-11 – 2005-09 · Bronchial Asthma
What this study did
NCT00476268 · Chiesi Farmaceutici S.p.A.
2004-02 – 2005-01 · Asthma
What this study did
NCT00382889 · Chiesi Farmaceutici S.p.A.
2002-08 – 2004-09 · Asthma
What this study did
NCT00000578 · National Heart, Lung, and Blood Institute (NHLBI)
1994-04 – 2000-10 · Asthma, Lung Diseases
What this study did
Phase 2 (1)
Asthma
NCT01584492 · Chiesi Farmaceutici S.p.A.
2011-12 – 2013-02 · Asthma
What this study did
Phase 4 (4)
Asthma
NCT02577497 · University of Virginia
2016-06 – 2018-07-06 · Asthma
What this study did
NCT02298205 · Washington University School of Medicine
2015-02 – 2017-10-31 · Asthma
What this study did
NCT01333800 · Grünenthal Colombiana S.A.
2010-07 – 2010-12 · Asthma
What this study did
NCT00395408 · Organon and Co
2000-06 – 2003-12 · Asthma
What this study did
Early phase / not applicable (1)
Asthma
NCT01142947 · Henry Ford Health System
2007-10 – 2019-03-11 · Asthma
What this study did

Competitive landscape

This mechanism is crowded: 23 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Asthma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Beclomethasone (QVAR): this drugApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT02040766: Baseline-adjusted trough morning percent predicted FEV1, AUEC(0-12 wk) vs placebo: BDP 80 ug/day BAI +2.81 (95% CI 0.80 to 4.82), p=0.0063; BDP 160 ug/day BAI +0.63, p=0.5332; BDP 80 ug/day MDI +0.92, p=0.3649; BDP 160 ug/day MDI +1.09, p=0.2823 (CT.gov posted results).
Albuterol (Armstrong Albuterol HFA)ApprovedSmall moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Albuterol (Ventolin)ApprovedSmall moleculeBeta-2 adrenergic receptorWeak signalNo reviewed efficacy summary in this indication
Albuterol / Budesonide (Airsupra)ApprovedCombinationBeta-2 adrenergic receptor, Glucocorticoid receptorReliable signal
NCT05505734: Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212
NCT03769090: Number of Participants With a Severe Asthma Exacerbation Event (From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.): BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) 207/1013 | BDA MDI 80/180 μg (Full Analysis Set) 241/1054 vs AS MDI 180 μg (Full Analysis Set; >=12 Years) 266/1014 | AS MDI 180 μg (Full Analysis Set) 276/1056
Albuterol Sulfate (Amphastar)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Albuterol Sulfate (Proventil HFA)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
AminophyllineApprovedSmall moleculePhosphodiesterase (multi-subtype)not yet gradedNo reviewed efficacy summary in this indication
Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate (Trimbow)
ApprovedUS marketing discontinued
Small moleculeGlucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signalNo reviewed efficacy summary in this indication
Benralizumab (Fasenra)ApprovedMonoclonal antibodyIL-5 receptor alpha, IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC), IL-5 receptor alpha (IL5RA) on eosinophils/basophilsReliable signal
NCT03170271: Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24) (Baseline (Week 0) up to Week 24): Benralizumab 0.94 Events/year (95% CI 0.79 to 1.12) | Placebo 1.86 Events/year (95% CI 1.54 to 2.24)
NCT01928771: Annual asthma exacerbation rate: 0.73 events/year with benralizumab 30 mg q4w vs 1.33 with placebo (rate ratio 0.55, 95% CI 0.42-0.71; p<0.001); 0.65 events/year with benralizumab 30 mg q8w vs 1.33 with placebo (rate ratio 0.49, 95% CI 0.37-0.64; p<0.001).
Betamethasone Dipropionate Emollient Spray (Sernivo)
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Budesonide (Pulmicort)ApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Entocort EC)
Approved(overall)
Small moleculeGlucocorticoid receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
Budesonide (Ortikos)
ApprovedUS marketing discontinued (overall)
—Glucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Budesonide (Pulmicort Flexhaler)ApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Budesonide (targeted-Release) (TARPEYO / Nefecon)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Budesonide (Uceris Rectal Foam)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Budesonide / Formoterol Fumarate (SYMBICORT)ApprovedCombinationGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00646321: Evening PEF (primary) better with once- or twice-daily budesonide/formoterol than budesonide alone (P<or=.027).
Budesonide MMX (Uceris)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere)ApprovedSmall moleculeGlucocorticoid receptor; Muscarinic M3; Beta-2 adrenergicPartial signal
NCT04609878: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.281 Liters (Standard Error 0.018) | BGF MDI 320/28.8/9.6 μg BID 0.316 Liters (Standard Error 0.014) vs BFF MDI 320/9.6 μg BID 0.249 Liters (Standard Error 0.014) | Symbicort® pMDI 320/9 μg BID 0.22 Liters (Standard Error 0.014)
NCT04609904: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.374 Liters (Standard Error 0.019) | BGF MDI 320/28.8/9.6 μg BID 0.354 Liters (Standard Error 0.015) vs BFF MDI 320/9.6 μg BID 0.219 Liters (Standard Error 0.015) | Symbicort® 320/9 μg BID 0.239 Liters (Standard Error 0.015)
Ciclesonide (Alvesco)ApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT00174720: FEV1 change from baseline, source's own labeled primary endpoint (average of weeks 12 and 16): ciclesonide 80mcg b.i.d. +0.30L (p<0.0001), 160mcg q.d. +0.19L (p<0.0001), 80 b.i.d./160 q.d. stepped +0.19L (p<0.0001), vs placebo +0.06L (p=0.0251); at week 16 alone, all ciclesonide arms significant vs placebo (p<=0.015), magnitude not given for week 16 alone
NCT00163397: Change in FEV1: non-inferiority of ciclesonide to budesonide demonstrated (one-sided p = 0.0021), confirmed in the ITT analysis
DepemokimabApprovedMonoclonal antibodyIL-5Partial signal
NCT04719832: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Placebo 1.11 Exacerbation per participant per year (95% CI 0.86 to 1.43) | GSK3511294 0.46 Exacerbation per participant per year (95% CI 0.36 to 0.58)
Dexamethasone
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Dexamethasone (Dextenza)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphaPartial signal
NCT03782532: Change in pre-bronchodilator FEV1, baseline to Week 12: LS mean difference 0.31 L favoring dupilumab vs placebo (95% CI 0.23-0.39); p<0.0001 (primary analysis population, n=414).
Fluticasone Furoate (Arnuity Ellipta)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT00603278: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 100 µg OD 0.142 Liters (Standard Error 0.0403) | GW685698X 200 µg OD 0.173 Liters (Standard Error 0.0404) | GW685698X 300 µg OD 0.228 Liters (Standard Error 0.0402) | GW685698X 400 µg OD 0.215 Liters (Standard Error 0.0414) vs Placebo -0.065 Liters (Standard Error 0.0395) | FP 250 µg BID 0.16 Liters (Standard Error 0.0409)
NCT00603382: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 25 µg OD 0.239 Liters (Standard Error 0.0428) | GW685698X 50 µg OD 0.266 Liters (Standard Error 0.042) | GW685698X 100 µg OD 0.341 Liters (Standard Error 0.0396) | GW685698X 200 µg OD 0.367 Liters (Standard Error 0.0428) vs Placebo 0.137 Liters (Standard Error 0.0428) | FP 100 µg BID 0.243 Liters (Standard Error 0.0411)
Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signal
NCT02924688: Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001).
NCT04937387: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (100ug FF) (Baseline (pre-dose at Day 1) and Week 12): Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug 0.136 Liters (Standard Error 0.0316) vs Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug 0.078 Liters (Standard Error 0.0321)
Fluticasone Furoate / Vilanterol (Breo Ellipta)ApprovedSmall moleculeBeta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptorReliable signal
NCT01086384: Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010
NCT03248128: Absolute Weighted Mean of Forced Expiratory Volume in 1 Second (FEV1) (0-4 Hours) at Week 12 in 5-17 Year Old Population (Week 12): Participants Who Received FF/ VI FDC 2.082 Liters (Standard Deviation 0.7598) vs Participants Who Received FF 1.994 Liters (Standard Deviation 0.6998)
Fluticasone PropionateApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Fluticasone Propionate / Salmeterol (Advair Diskus)ApprovedSmall moleculeGlucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT00920959: Change in percent predicted PM PEF: FSC 100/50 QD did not give significantly greater improvement than FP 100 QD (superiority not shown) missed
Fluticasone Propionate / Salmeterol (Advair HFA)ApprovedCombinationGlucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptorPartial signal
NCT00448435: Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53)
Halobetasol Propionate Foam (Lexette)
ApprovedUS marketing discontinued (overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Halobetasol Propionate Lotion (Bryhali)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Hydrocortisone (Cortenema)
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Hydrocortisone Acetate (Cortifoam)
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Levalbuterol (Xopenex HFA)Approved—beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Mepolizumab (Nucala)ApprovedMonoclonal antibodyIL-5, Interleukin-5 (IL-5), ligand-neutralizingWeak signal
NCT01691508: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Mepolizumab 100 mg SC — 90 to 100%: 16/69; 75 to <90%: 12/69; 50 to <75%: 9/69; >0 to <50%: 7/69; No decrease /lack of asthma control/early WD: 25/69 vs Placebo — 90 to 100%: 7/66; 75 to <90%: 5/66; 50 to <75%: 10/66; >0 to <50%: 7/66; No decrease /lack of asthma control/early WD: 37/66
NCT01000506: Number of Clinically Significant Exacerbations of Asthma Per Year (From randomization (Week 0) to Week 52 or early withdrawal (EW)): Mepolizumab 75 mg IV 1.24 Exacerbations per year | Mepolizumab 250 mg IV 1.46 Exacerbations per year | Mepolizumab 750 mg IV 1.15 Exacerbations per year vs Placebo IV 2.4 Exacerbations per year
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mometasone Furoate / Formoterol Fumarate (Dulera / Zenhale)ApprovedSmall moleculeGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00383240: Primary endpoint (FEV1 AUC(0-12h) change from baseline to week 12, L*h), MF/F 200/10 mcg vs MF 200 mcg alone: 3.19 (SD 3.98) vs 1.31 (SD 3.98); p<.001.
NCT00383552: AUC(0-12h) change from baseline to Week 12 in FEV1: MF/F 100/10 mcg BID +4.00 L*h (SD 3.71) vs MF 100 mcg BID +2.53 L*h (SD 3.71); ANCOVA p=0.001.
Montelukast (Singulair)ApprovedSmall moleculeCysteinyl leukotriene receptor 1 (CysLT1)Weak signal
NCT00489346: Primary endpoint (percentage of asthma rescue-free days over 12 months): montelukast 5mg QD (n=495) was non-inferior to fluticasone 100mcg BID (n=499) — 495+499=994, exactly matching this record's enrollment. LS mean difference -2.8% (95% CI -4.7% to -0.9%), within the pre-specified -7% noninferiority margin.
Omalizumab (Xolair)ApprovedMonoclonal antibodyIgE (immunoglobulin E), IgEWeak signalNo reviewed efficacy summary in this indication
Primatene MistApprovedSmall moleculeAdrenergic receptor (non-selective, alpha+beta), Alpha-1 and beta-1/beta-2 adrenergic receptors, Adrenergic receptors, nonselectivePartial signal
NCT01460511: Primary endpoint, AUC0-6h of percent change in FEV1 at week 4: numerical benefit of epinephrine HFA over placebo, not statistically significant (two-sided p=0.125, per-protocol analysis; supported by the ITT and three sensitivity analyses). FDA judged the trial underpowered. missed
NCT01357642: Primary endpoint, AUC0-6h of percent change in FEV1 at week 12 (ITT): epinephrine HFA 250 mcg 40.59 (SD 56.09, n=248) vs placebo 12.76 (SD 55.77, n=61); mean difference 27.83 (95% CI 11.99 to 43.68), p<0.05. Epinephrine CFC active control: 35.67 (SD 45.70, n=64).
Relacorilant (Lifyorli)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Salmeterol (DISKUS)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
TerbutalineApprovedSmall moleculeBeta-2 adrenergic receptor (ADRB2)not yet gradedNo reviewed efficacy summary in this indication
Tezepelumab (Tezspire)ApprovedMonoclonal antibodyTSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizingReliable signal
NCT03347279: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma (From randomisation to Study Week 52.): Tezepelumab 210mg Q4W 0.93 events per year (95% CI 0.8 to 1.07) | Placebo 2.1 events per year (95% CI 1.84 to 2.39)
NCT03406078: Categorized Percent Reduction From Baseline in the Daily OCS Dose While Not Losing Asthma Control (Baseline to Week 48): Tezepelumab — >=90% to <=100% reduction: 40/74; >=75% to <90% reduction: 5/74; >=50% to <75% reduction: 10/74; >0% to <50% reduction: 5/74; no change or any increase: 14/74 vs Placebo — >=90% to <=100% reduction: 35/76; >=75% to <90% reduction: 4/76; >=50% to <75% reduction: 14/76; >0% to <50% reduction: 9/76; no change or any increase: 14/76 missed
Tiotropium BromideApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)Reliable signal
NCT00772538: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks): Tio R5 0.401 Liter (Standard Error 0.025) vs Placebo 0.315 Liter (Standard Error 0.026)
NCT00565266: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) (AM PEF was measured daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.): Tio + 1xICS 24.4 Liters per minute (Standard Error 4.2) vs LABA + 1xICS 18 Liters per minute (Standard Error 3.2) vs 2xICS -1.4 Liters per minute (Standard Error 3.5)
Beclomethasone Dipropionate / Formoterol FumaratePhase 3Small moleculeGlucocorticoid receptor; β2-adrenergic receptorReliable signal
NCT05292586: 1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12 (Baseline (pre-dose on Week 0) and Week 12.): CHF 1535 pMDI 0.279 liter (95% CI 0.248 to 0.309) vs CHF 718 pMDI 0.174 liter (95% CI 0.143 to 0.206)
FelcorekibartPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
FenoterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Fenoterol / Ipratropium BromidePhase 3Small moleculeMuscarinic M3 receptor / Beta-2 adrenergic receptor (combination), Muscarinic acetylcholine receptor M3 and beta-2 adrenergic receptorReliable signal
NCT02182479: Primary, average FEV1 change from test-day baseline over 6 hours after dosing on day 85, non-inferiority of Respimat SMI (10/25 mcg and 20/50 mcg) vs pMDI (20/50 mcg): neither Respimat dose was inferior to the pMDI (p<0.001), met. Supportive: mean peak FEV1 increase on day 85 was 0.498 to 0.521 L with active treatment vs 0.215 and 0.240 L with placebo.
Indacaterol Maleate / Mometasone FuroatePhase 3—Glucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT02554786: Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 (26 weeks): QMF149 150/320 μg 2.383 litre (L) (Standard Error 0.0159) | QMF149 150/160 μg 2.387 litre (L) (Standard Error 0.016) | MF 800 μg 2.25 litre (L) (Standard Error 0.0162) | MF 400 μg 2.176 litre (L) (Standard Error 0.0162) | Salmeterol/Fluticasone 50/500 μg 2.346 litre (L) (Standard Error 0.016)
NCT02892344: Trough FEV1 (week 12): QMF149 150/80 μg 2.562 Liters (Standard Error 0.0134) | MF 200 µg 2.379 Liters (Standard Error 0.0134)
IpratropiumPhase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesPartial signal
NCT01449162: Annualized severe asthma exacerbation rate (SAER), primary population, overall treatment exposure: masitinib reduced SAER by 35% vs placebo; rate ratio 0.65 (95% CI 0.47-0.90; P=0.010)
NCT03771040: Severe asthma exacerbations: 29% reduction vs placebo (p=0.022) in patients with eosinophils above 150/uL
OcankitugPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
Oxitropium Bromide (Ba253BINEB)Phase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
RademikibartPhase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Salbutamol HFA-152aPhase 3Small moleculeBeta-2 adrenergic receptorWeak signal
NCT06261957: Primary outcomes, safety (no formal efficacy test): participants with an adverse event in the treatment period 108/338 (HFA-152a) vs 36/112 (HFA-134a); none in the run-in period (0/471); serious adverse events 6/338 vs 3/112 (CT.gov posted results).
TilrekimigPhase 3Multispecific antibodyIL-4/IL-13/TSLPnot yet gradedNo reviewed efficacy summary in this indication
VilanterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signal
NCT00600171: Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036)
Glycopyrronium (PT001)Phase 2/3Small moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT03358147: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412)
StapokibartPhase 2/3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
WIN378Phase 2/3Monoclonal antibodyTSLPWeak signalFeatured results are safety only in this race
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
ARO-RAGEPhase 2RNA / oligonucleotideRAGE (receptor for advanced glycation end-products)Weak signalFeatured results are safety only in this race
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
Dazucorilant
Phase 2(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
ENV-294Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Freneslerbart / MevonlerbartPhase 2Monoclonal antibodyFel d 1 (major cat allergen protein)Reliable signal
NCT03838731: Primary endpoint, time to early asthmatic reaction at Week 1 following single dose: >4 hours (REGN1908-1909) vs 51 minutes (placebo), p=0.0083
FrevecitinibPhase 2Small moleculeJAK1/2/3/TYK2Weak signalNo reviewed efficacy summary in this indication
KT-621Phase 2Small moleculeSTAT6not yet gradedNo reviewed efficacy summary in this indication
LunsekimigPhase 2Antibody-derived scaffoldTSLP + IL-13Weak signalFeatured results are safety only in this race
Miricorilant
Phase 2(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
PBF-680Phase 2—Adenosine A1 receptorPartial signal
NCT03774290: Trough FEV1 change from baseline at Day 16: placebo 2.88±0.10 L vs PBF-680 3.06±0.09 L; +180 mL mean increase over placebo (P=0.0816, pre-specified alpha=0.1)
QuisovalimabPhase 2Monoclonal antibodyLIGHT (TNFSF14)Partial signal
NCT05288504: Participants with an asthma-related event through week 14: AVTX-002 12 vs placebo 14 (CT.gov posted counts); the sponsor states the primary endpoint was not met. missed
RC1416Phase 2Multispecific antibodyIL-4 / IL-5 / IL-13not yet gradedNo reviewed efficacy summary in this indication
RilzabrutinibPhase 2Small moleculeBTKPartial signal
NCT05104892: Primary endpoint (LOAC events at Week 12): high-dose rilzabrutinib 36% relative risk reduction vs placebo (OR 0.584, 95% CI 0.253-1.349); low-dose 25% relative risk reduction (OR 0.570, 95% CI 0.202-1.608). missed
SunakimentPhase 2Antibody fragmentTSLPPartial signalFeatured results are safety only in this race
TozorakimabPhase 2Monoclonal antibodyIL-33Partial signal
NCT04570657: Change from baseline to week 16 in clinic pre-bronchodilator FEV1 vs placebo (LSMD, 80% CI): tozorakimab 600 mg +4 mL (-71 to 79), p=0.473; tozorakimab 300 mg +36 mL (-38 to 111), p=0.267 missed
Umeclidinium (Incruse Ellipta)Phase 2Small moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT01573624: Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period): FF 100 mcg + UMEC 15.6 mcg 0.026 Litres (L) (95% CI -0.0098 to 0.0611) | FF 100 mcg + UMEC 31.25 mcg 0.032 Litres (L) (95% CI -0.0036 to 0.0679) | FF 100 mcg + UMEC 62.5 mcg 0.0385 Litres (L) (95% CI -0.0011 to 0.0745) | FF 100 mcg + UMEC 125 mcg 0.0444 Litres (L) (95% CI 0.0067 to 0.0813) | FF 100 mcg + UMEC 250 mcg 0.051 Litres (L) (95% CI 0.0139 to 0.0873)
NCT01641692: Final Dose-response Model for Trough Forced Expiratory Volume in One Second (FEV1) (Day 15 of each treatment period (up to Study Day 71)): All Study Treatments — Theta1 (mean Baseline): 0.0363 unitless (95% CI 0.028 to 0.045); Theta2 (period Baseline): -0.97 unitless (95% CI -1.06 to -0.881); Omega (mean Baseline): 0.00371 unitless (95% CI 0.002 to 0.005); Omega (period Baseline): 0.149 unitless (95% CI 0 to 0.298); Sigma (Variance of Residual error): 0.0393 unitless (95% CI 0.028 to 0.05)
VerekitugPhase 2Monoclonal antibodyTSLP receptorReliable signal
NCT06196879: Annualized Asthma Exacerbation Rate (AAER) reduction vs placebo (VALIANT): -56% at verekitug 100 mg q12w (p<0.0003); -39% at 400 mg q24w (p<0.02)
AMG 691Phase 1——not yet gradedNo reviewed efficacy summary in this indication
AZD0449Phase 1—JAK1Partial signalFeatured results are safety only in this race
Lodotra (Rayos)Discontinued—Glucocorticoid receptorWeak signal
NCT00686335: Total Number of Nocturnal Awakenings During the Last 2 Weeks of Treatment (4 weeks and 8 weeks): Lodotra 2.1 number of nocturnal awakenings (Standard Deviation 4.41) vs Cortancyl 10 number of nocturnal awakenings (Standard Deviation 5.45)

Large race: only the 83 furthest-along competitors are listed; 19 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

No upcoming readouts on record for this asset.